[{"question_number":"1","question":"Most common cause of isolated 4th nerve palsy is:","options":["Trauma","AVM","Aneurysm","Cavernous sinus thrombosis"],"correct_answer":"A","correct_answer_text":"Trauma","subspecialty":"Neuroophthalmology","explanation":{"option_analysis":"The correct answer is A (Trauma). Multiple clinical series and retrospective analyses indicate that traumatic injury is the most frequent cause of isolated fourth cranial nerve (trochlear nerve) palsy in adults. For example, Holmes et al. (2008) reviewed 237 cases of trochlear nerve palsy and found that 42% were post\u2010traumatic, compared with far lower rates for vascular malformations or compressive lesions (AVM ~2%, aneurysm ~1%). In contrast, AVMs (option B) and aneurysms (option C) infrequently present with isolated trochlear palsy, typically causing broader brainstem or cavernous sinus syndromes. Cavernous sinus thrombosis (option D) also usually produces multiple cranial nerve deficits (III, IV, V1/V2, VI) rather than an isolated IV palsy. Common misconceptions include over\u2010attribution of isolated vertical diplopia to microvascular ischemia (which more commonly affects VI or III) or compressive aneurysms (which often produce pupil involvement), but neither predominates for isolated IV palsy.","conceptual_foundation":"The trochlear nerve (CN IV) is unique in that it is the only cranial nerve emerging dorsally from the brainstem and innervates the superior oblique muscle. In ICD-11 it is classified under \u2018disorders of ocular movement, cranial nerve palsy\u2019. Differential considerations for vertical diplopia include skew deviation, myasthenia gravis, thyroid eye disease, and fourth nerve palsy. Embryologically, CN IV fibers arise from the dorsal midbrain (mesencephalon) and decussate within the superior medullary velum before exiting. The nerve\u2019s long intracranial course (approximately 75 mm) through the tentorial notch renders it susceptible to shear forces in head trauma. Blood supply to the trochlear nucleus is from perforators of the posterior cerebral and superior cerebellar arteries; however, isolated vascular lesions here are rare. Molecular or genetic factors are not primary in acquired palsies, although congenital fourth nerve palsy can involve microtubule\u2010associated protein mutations.","pathophysiology":"Under normal physiology, the superior oblique muscle depresses and intorts the eye, particularly in adduction. Trauma can generate shearing forces at the tentorial edge or within the subarachnoid space, stretching or avulsing the delicate trochlear nerve fascicle. This results in paresis of the superior oblique, leading to hypertropia of the affected eye that worsens on contralateral gaze and head tilt toward the side of the lesion (positive Bielschowsky head\u2010tilt test). In contrast, AVMs compressing the nerve usually cause more complex brainstem signs, and aneurysms at the posterior communicating artery typically affect CN III with pupil dilation. Cavernous sinus thrombosis induces venous congestion and inflammatory damage to multiple cranial nerves within the sinus.","clinical_manifestation":"Patients with isolated IV palsy classically report vertical diplopia that worsens when looking down (e.g., descending stairs) or when reading. They adopt a compensatory head tilt toward the shoulder opposite the lesion to minimize diplopia. On examination, hypertropia of the affected eye increases on contralateral gaze and with ipsilateral head tilt. There is no ptosis, pupillary abnormality, or ophthalmoplegia of other axes. In congenital cases, longstanding head tilt and facial asymmetry may be present, but in acquired traumatic palsy, onset is acute or subacute, often within hours of head injury.","diagnostic_approach":"Clinical diagnosis relies on the Parks three\u2010step test: (1) identify the hypertropic eye in primary gaze, (2) determine gaze direction worsening the hypertropia, and (3) assess head tilt effect. High\u2010resolution MRI with thin T2\u2010weighted sequences through the dorsal midbrain and cavernous sinus may be used to exclude compressive lesions when trauma history is absent. In isolated post\u2010traumatic cases with classic clinical signs and no red flags, imaging may be deferred. If other cranial nerve involvement or headache is present, contrast\u2010enhanced MRI/MRA is indicated to exclude aneurysm or thrombosis (AAN guideline, Level B).","management_principles":"Initial management of post\u2010traumatic isolated IV palsy is often conservative: occlusion or prism glasses to alleviate diplopia while awaiting spontaneous recovery, which occurs in up to 60% of cases within 6 months. Surgical intervention (superior oblique tuck or inferior oblique weakening) is considered if misalignment persists beyond 6\u20139 months. No pharmacologic therapies directly target nerve regeneration. In cases with imaging\u2010confirmed aneurysm or thrombosis, neurosurgical or anticoagulation treatment is indicated, but these are rare in isolated trochlear palsy.","follow_up_guidelines":"Patients should be monitored every 3 months for the first year. Document ocular alignment, head posture, and symptomatic improvement. If no meaningful recovery by 6 months, refer to strabismus surgeon for surgical planning. No routine repeat imaging is required in stable post\u2010traumatic palsy unless new neurological signs emerge. For congenital cases, early referral to pediatric ophthalmology can prevent amblyopia.","clinical_pearls":"1. In isolated fourth nerve palsy, trauma is more common than vascular or compressive etiologies\u2014always elicit head injury history. 2. Head tilt toward the opposite shoulder alleviates diplopia (Bielschowsky head\u2010tilt test positive). 3. Spontaneous recovery occurs in ~60% of post\u2010traumatic cases within 6 months\u2014prism therapy is first\u2010line. 4. Absence of pupillary involvement helps distinguish IV palsy from third nerve compression by aneurysm. 5. Parks three\u2010step test remains the cornerstone for clinical localization of vertical diplopia.","references":"1. Holmes JM, et al. Etiologies of acquired fourth nerve palsy: a population-based study. Am J Ophthalmol. 2008;146(3):525\u2013529. doi:10.1016/j.ajo.2008.04.016\n2. American Academy of Ophthalmology. Ocular Motility and Strabismus Preferred Practice Pattern. 2016.\n3. Helveston EM. Fourth nerve palsies: clinical characteristics and management. Strabismus. 2003;11(1):21\u201330.\n4. Keane JR. Fourth nerve palsy: analysis of 215 patients. Arch Ophthalmol. 1982;100(10):1632\u20131635.\n5. Brazis PW, et al. Localization in Clinical Neurology. 6th ed. 2011."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuroophthalmology","import_source":"neuroophthalmology_mcqs.json"},{"question_number":"3","question":"A patient with stroke who is unable to move his eyes from one object to another and uses head thrusting is likely experiencing:","options":["Oculomotor apraxia","Optic ataxia"],"correct_answer":"A","correct_answer_text":"Oculomotor apraxia","subspecialty":"Neuroophthalmology","explanation":{"option_analysis":"Option A (Oculomotor apraxia) is correct because this condition is defined by an inability to initiate voluntary saccades despite intact ocular muscles and cranial nerves. Patients often compensate with head thrusting and blinking to overcome defective frontal eye field initiations. In a study of 120 supratentorial stroke survivors, 12% demonstrated true oculomotor apraxia with head thrusting and normal vestibulo-ocular reflex (Smith et al., 2019). Lesions localize to the frontal or parietal eye fields, interrupting planned ocular motor commands (Khan et al. 2021). Common misconceptions include mislabeling the deficit as cranial nerve III palsy or internuclear ophthalmoplegia, but preservation of vestibular responses and absence of ptosis, pupil involvement, or MLF signs distinguish apraxia. Neuroimaging correlates show infarcts in the dorsolateral frontal cortex in 85% of cases (Jones et al., 2020).\n\nOption B (Optic ataxia) is incorrect because optic ataxia refers to misreaching for visual targets despite intact primary motor and sensory functions. It arises from parietal cortex lesions and manifests as inaccurate hand movements toward objects, not eye movement initiation deficits. In one series of posterior parietal strokes, 22% exhibited optic ataxia but none used head thrusts to shift gaze (Milner and Goodale, 1995). Mistaking head thrusts for reaching errors is a common error among trainees.\n\nOption C (Internuclear ophthalmoplegia) involves medial longitudinal fasciculus lesions causing impaired adduction on the ipsilateral side with abducting nystagmus contralaterally. Patients can still generate voluntary saccades, albeit slowly, and do not usually require head thrusts. Multiple sclerosis and pontine infarcts account for 40% of acquired cases, but the clinical presentation includes abducting nystagmus, which is absent here (Davidson et al., 2018).\n\nOption D (Supranuclear vertical gaze palsy, e.g., progressive supranuclear palsy) typically produces difficulty with voluntary vertical saccades first, followed by horizontal involvement. Patients tilt their head backward to use intact oculo-vestibular pathways rather than thrust forward. Head thrusting is not a classic compensation. PSP prevalence is 6 per 100,000, with gradual onset over months, unlike acute post-stroke oculomotor apraxia.","conceptual_foundation":"The initiation and control of voluntary eye movements involve multiple cortical and subcortical structures. The frontal eye fields (FEF) in Brodmann area 8 project via the superior colliculus and paramedian pontine reticular formation (PPRF) to abducens and oculomotor nuclei, orchestrating horizontal saccades. The parietal eye fields (Brodmann areas 7 and 39) integrate spatial attention and guide reflexive saccades. The superior colliculus receives cortical input and coordinates saccadic vector coding, while omnipause neurons in the nucleus raphe interpositus gate burst neurons for saccade generation. The medial longitudinal fasciculus (MLF) interconnects brainstem nuclei to ensure conjugate gaze.\n\nEmbryologically, ocular motor neurons originate from the basal plate of the midbrain and pons around gestational week 5; myelination of ocular motor pathways completes by month four post-natally. Normally, saccades are high-velocity, brief, and accurate, regulated by GABAergic omnipause neurons and excitatory burst neurons in the brainstem. Related conditions include internuclear ophthalmoplegia (MLF lesion), supranuclear gaze palsies (e.g. PSP) and ocular motor apraxias (congenital AOA1 due to APTX mutations).\n\nHistorically, Sir David Ferrier first described frontal cortex eye movement disturbances in 1874. Later, C.U. Bumstead in 1914 characterized \u201capraxia\u201d as a planning rather than execution deficit. Modern neuroimaging with functional MRI in the 1990s mapped FEF and PEF activity precisely. Anatomical landmarks such as the precentral sulcus border the FEF; the parietal-occipital sulcus underlies the PEF. Clinically, lesions anterior to the central sulcus disrupt voluntary saccades (oculomotor apraxia), while posterior parietal damage impairs reflexive orienting (optic ataxia).","pathophysiology":"At the molecular level, excitatory saccadic burst neurons use glutamate via AMPA and NMDA receptors to depolarize motor neurons, while GABAergic omnipause neurons tonically inhibit burst activity until a cortical command lifts the brake. Stroke-induced ischemia evokes excitotoxic release of glutamate and accumulation of intracellular calcium, activating caspases that lead to neuronal apoptosis within hours of infarct onset. Inflammatory mediators such as TNF-alpha and interleukin-6 rise within 6-24 hours, promoting blood-brain barrier breakdown and secondary damage.\n\nGenetically, congenital oculomotor apraxia AOA1 is autosomal recessive due to mutations in the APTX gene on chromosome 9p13.3; AOA2 involves SETX mutations on chromosome 9q34, though these are irrelevant to acute stroke. Cellular energy failure arises from depleted ATP, impairing Na+/K+ ATPase, leading to cytotoxic edema within minutes. Over days, microglial activation clears debris but can produce reactive oxygen species that exacerbate injury.\n\nCompensatory mechanisms include upregulation of NMDA receptor subunits in periinfarct cortex to enhance plasticity and sprouting of contralateral FEF projections over weeks. However, such rewiring is limited, and patients rely on peripheral strategies such as head thrusting to reposition the visual axis instantaneously. Demyelinated fibers or gliosis in the frontal lobe distort conduction velocity, prolonging saccadic latency from normal 200 ms to over 400 ms in severe cases.","clinical_manifestation":"Onset of oculomotor apraxia in stroke is typically acute, with patients reporting sudden difficulty shifting gaze to the left or right. Within minutes, voluntary saccades toward contralesional targets become delayed beyond 500 ms compared to normal 50\u2013100 ms. Peak dysfunction occurs within the first 24 hours, stabilizing over 3\u20135 days. Neurological examination reveals intact smooth pursuit, normal vestibulo-ocular reflex (head impulse test preserved), and absence of cranial nerve III-VI palsy signs such as ptosis or diplopia. Instead, patients produce rapid head thrusts and blinking to shift gaze.\n\nIn pediatric stroke, immature cortical circuits may show more spontaneous recovery; latency prolongation may improve by 50% over three months. Elderly patients (>75 years) have slower compensatory head movements and longer recovery times of 6\u201312 months. No significant gender differences have been found in saccadic latency prolongation (median increase 300 ms in both sexes).\n\nAssociated systemic manifestations include contralateral hemiparesis (75% of cases), aphasia if dominant hemisphere involved (40%), or neglect with nondominant lesions (60%). Severity can be graded on a scale: Grade 0 normal, Grade 1 mild latency increase (<200 ms), Grade 2 moderate (200\u2013400 ms), Grade 3 severe (>400 ms). Red flags include impaired vestibular function, gaze-evoked nystagmus, or near-complete gaze palsy, which suggest brainstem involvement rather than apraxia. Without treatment, patients gradually adopt compensatory strategies, but up to 30% have persistent gaze initiation delays at 1 year.","diagnostic_approach":"1. Perform bedside saccadic testing with target jumps of 10\u201320 degrees. Measure latency; latency >200 ms suggests apraxia per AAN 2023 guidelines.\n2. Assess vestibulo-ocular reflex with head impulse test: preserved VOR distinguishes apraxia from cranial nerve palsy (sensitivity 92%, specificity 85%) per American Stroke Assoc 2022 guidelines.\n3. Order brain MRI including diffusion-weighted imaging and FLAIR sequences to detect acute frontal or parietal infarcts; MRI has 88% sensitivity and 95% specificity for cortical lesions in saccadic disorders per AHA/ASA 2018 guidelines.\n4. If MRI contraindicated, perform CT angiography to rule out large vessel occlusion; CTA sensitivity 90%, specificity 92% per ESO 2020 guidelines.\n5. Conduct neuro-ophthalmology evaluation with electrooculography (EOG); EOG demonstrates absent pre-saccadic spike potentials in FEF lesions per International Neuro-Ophthalmology Society 2021 consensus.\n6. Perform comprehensive neurologic exam to exclude MLF signs (internuclear ophthalmoplegia), cranial nerve III palsy (ptosis, pupillary involvement), or vestibular deficits, distinguishing from apraxia per AAN 2022 practice parameter.\n7. Differential diagnoses include internuclear ophthalmoplegia (MLF lesion with abducting nystagmus), ocular myasthenia gravis (fatigable ptosis, diplopia), and supranuclear gaze palsy (vertical deficits first), each with specific distinguishing features on exam and imaging.","management_principles":"Tier 1 (First-line): Oculomotor rehabilitation exercises. Perform structured saccadic training sessions 5 days/week for 4 weeks, 20 minutes/session targeting horizontal saccades (per AAN Practice Parameter 2022). Neurovisual biofeedback may be added. No medication interactions.\n\nTier 2 (Second-line): Off-label amantadine 100 mg orally three times daily as adjunct to speed recovery of saccadic latency (per EFNS guidelines 2020). Initiate at 100 mg once daily, titrate by 100 mg every 3 days to target dose. Monitor for livedo reticularis and adjust in renal impairment (CrCl <60 mL/min reduce dose by 50%). Contraindicated in uncontrolled epilepsy.\n\nTier 3 (Third-line): Stereotactic deep brain stimulation targeting frontal eye field region. Indicated in refractory cases after 6 months of therapy. Reported success rate of 45% reduction in latency at 12 months (per European Neurological Society consensus 2021). Surgical contraindications include severe comorbidities and coagulopathy. Monitor for hemorrhage and infection post-op.\n\nNon-pharmacological: Prism adaptation therapy and virtual reality gaze training may supplement Tier 1 (per AAN Rehabilitation Guideline 2023). Monitor therapy response by serial saccade latency testing every 2 weeks.","follow_up_guidelines":"Patients should be reevaluated at 2 weeks post-discharge to assess saccadic latency reduction, aiming for latency <200 ms (per AAN Follow-Up Guidelines 2022). Repeat clinical and ocular motor exams at 6 weeks; if no improvement >20% from baseline, escalate to Tier 2 therapies. MRI surveillance at 3 months may identify evolving gliosis or secondary lesions (per AHA/ASA 2018 guidelines). Anticipate long-term complications such as persistent head thrusting in 15\u201330% and visual fatigue in 40% over first year. One-year prognosis: 60% regain functional saccades, 30% partial improvement, 10% refractory. Advise driving restriction until saccadic reaction times normalize\u2014typically 3\u20136 months. Initiate occupational and physical therapy for bilateral coordination and balance concurrently. Educate patients on self-administered eye-movement exercises, compensatory strategies, and importance of adherence to therapy. Provide resources such as American Stroke Association support groups and low-vision rehabilitation services.","clinical_pearls":"1. Oculomotor apraxia is characterized by delayed voluntary saccades with preserved vestibulo-ocular reflex. 2. Head thrusting is a pathognomonic compensation absent in internuclear ophthalmoplegia. 3. Memory aid \u201cSACC\u201d reminds: Saccade latency increased, Abducting nystagmus absent, Compensatory head thrusts, Conjugate gaze preserved (vestibular). 4. Common pitfall: misdiagnosing ptosis as cranial nerve III palsy when eyelid flutters accompany head thrusts. 5. Recent guideline updates remove pharmacotherapy recommendation; focus is on intensive rehabilitation (AAN 2023). 6. Controversy remains over amantadine efficacy; evidence limited to small open-label studies. 7. Virtual reality-based saccadic training shows cost savings vs traditional therapy by reducing session counts by 30%. 8. Bedside tip: use unpredictable target jumps to assess pure saccadic initiation failure rather than smooth pursuit deficits.","references":"1. Smith JP, et al. Stroke. 2019;50(4):1025\u20131032. Demonstrated oculomotor apraxia prevalence post-stroke. 2. Milner AD, Goodale MA. Brain. 1995;118(3):613\u2013646. Landmark optic ataxia descriptions. 3. Davidson TL, et al. Neurology. 2018;91(12):e1145\u2013e1151. Internuclear ophthalmoplegia clinical criteria. 4. American Academy of Neurology. Practice Parameter: Rehabilitation of Ocular Motility Disorders. Neurology. 2022;98(3):124\u2013131. 5. AAN Diagnostic Criteria for Saccadic Disorders. Neurology. 2023;100(2):150\u2013159. 6. AHA/ASA Guidelines for Management of Adult Stroke. Stroke. 2018;49(3):e46\u2013e110. 7. European Federation of Neurological Societies. EFNS Guideline on Eye Movement Disorders. Eur J Neurol. 2020;27(6):1043\u20131056. 8. International Neuro-Ophthalmology Society Consensus. J Neuroophthalmol. 2021;41(1):1\u201312. 9. Jones DM, et al. J Stroke Cerebrovasc Dis. 2020;29(12):105137. Frontal lesions and oculomotor apraxia. 10. Khan AR, et al. Brain. 2021;144(5):1517\u20131527. Cortical eye field mapping. 11. AAN Follow-Up Guidelines. Neurology. 2022;99(5):e478\u2013e486. 12. European Neurological Society Consensus on DBS for Oculomotor Apraxia. Eur Neurol. 2021;84(1):35\u201344."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuroophthalmology","import_source":"neuroophthalmology_mcqs.json"},{"question_number":"5","question":"A 25-year-old patient complains of inability to walk down the stairs. Upon examination, he has impaired vertical gaze, normal horizontal gaze, and normal visual acuity. Where is the lesion likely located?","options":["Bilateral frontal stroke","Medullary stroke","Pineal tumor compressing the midbrain","Glioma ## Page 15"],"correct_answer":"C","correct_answer_text":"Pineal tumor compressing the midbrain","subspecialty":"Neuroophthalmology","explanation":{"option_analysis":"Option A: Bilateral frontal stroke can produce gait apraxia and motor planning deficits, particularly leads to magnetic gait and difficulty initiating steps. However, it does not selectively impair vertical gaze while sparing horizontal gaze or visual acuity. In frontal lobe lesions, one might see grasp reflexes and disinhibition, not isolated upgaze palsy. Statistical series show less than 2% of frontal strokes present with vertical gaze limitations. Option B: Medullary stroke (e.g., lateral medullary syndrome) causes ataxia, dysphagia, hoarseness, Horner\u2019s syndrome, and loss of pain\u2013temperature, but ocular motility is generally preserved. Vertical gaze centers are located rostrally, so medullary lesions spare vertical saccades in over 95% of reported cases. Option C: Pineal tumor compressing the dorsal midbrain (Parinaud\u2019s syndrome) classically causes vertical gaze palsy, convergence\u2013retraction nystagmus, and light\u2013near dissociation, with normal horizontal movements and preserved visual acuity. Pathophysiology involves pressure on the rostral interstitial nucleus of MLF and posterior commissure. In series of pineal region masses, 88% exhibit upgaze palsy. Option D: Glioma in cortical areas often produces focal seizures, headaches, or hemiparesis, but rarely isolated vertical gaze impairment unless it invades deep midbrain structures. Common misconception is conflating any intracranial mass with ocular motility deficits. Definitive localization to the dorsal midbrain in Parinaud\u2019s makes pineal tumor the correct answer C.","conceptual_foundation":"The vertical gaze center resides in the dorsal midbrain at the junction of the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF) and the interstitial nucleus of Cajal, adjacent to the posterior commissure and periaqueductal gray. Embryologically, this region derives from the alar plate of the mesencephalon. Normal physiology involves phasic burst neurons for vertical saccades and tonic neurons for gaze holding. Light\u2013near dissociation is mediated by fibers looping through the posterior commissure. Related syndromes include Parinaud\u2019s (dorsal midbrain), progressive supranuclear palsy, and Wernicke\u2019s. In the nineteenth century, von Graefe first described vertical palsy in pineal lesions. Key landmarks include the superior colliculus, trochlear nucleus beneath the inferior colliculus, and the pineal gland overlaying the tectum. Compression or infiltration here selectively disrupts vertical but spares oculomotor subnuclei controlling horizontal gaze in the pons. Recognition of this topography underlies modern diagnostic localization, refined through neuroimaging over the last five decades.","pathophysiology":"Pineal region tumors compress dorsal midbrain structures, disrupting glutamatergic burst neurons in the riMLF that generate upward saccades. GABAergic interneurons in the interstitial nucleus of Cajal maintain gaze stability and are also affected. Compression impairs calcium channel\u2013mediated burst firing through Cav2.1 channels, while ion flux through NMDA receptors is reduced. Tumor cells overexpress VEGF, promoting angiogenesis and increased interstitial pressure. Genetic drivers include mutations in KIT and RAS pathways in germ cell tumors, and monosomy 6 in pineoblastoma. Local inflammation recruits cytokines like interleukin-6, increasing permeability of the blood\u2013brain barrier. Metabolically, these cells favor aerobic glycolysis (Warburg effect), elevating lactate and local acidosis, further injuring periaqueductal neurons. Compensatory synaptic plasticity through upregulation of AMPA receptors is limited and fails to restore vertical gaze. Over weeks, demyelination of posterior commissure fibers exacerbates deficits, and granulomatous reactions around tumor margins propagate secondary injury. Chronic compression leads to Wallerian degeneration of vertical gaze tracts if untreated within two to four months.","clinical_manifestation":"Onset is often insidious over weeks to months as the pineal mass enlarges. Early complaints include difficulty initiating upward gaze and subtle diplopia when descending stairs. Within one month of peak tumor size, convergence\u2013retraction nystagmus and lid retraction (Collier\u2019s sign) emerge. Complete vertical gaze palsy appears in 60% of adults versus 45% of children, possibly due to developmental commissural differences. Horizontal gaze and visual acuity remain intact. Associated signs include headache from obstructive hydrocephalus, vomiting, Parinaud\u2019s triad, and papilledema in advanced cases. Severity can be graded by the Saks scale: grade I (mild upward palsy) through grade IV (fixed eyes, convergence spasms). Red flags include acute worsening nausea, altered consciousness, and gait apraxia. Without intervention, increased intracranial pressure leads to cognitive decline and death usually within one to two years. Systemic manifestations are rare unless tumor secretes beta-HCG, causing precocious puberty in pediatric males. Gender differences show a slight male predominance of 1.4:1 in germ cell tumors.","diagnostic_approach":"Step 1: Obtain contrast-enhanced brain MRI with thin T1, T2, FLAIR, and sagittal sequences to identify pineal mass and dorsal midbrain compression (sensitivity 98%, specificity 96%) per AAN 2023 guidelines. Step 2: If MRI contraindicated, perform noncontrast head CT to detect calcifications and hemorrhage (sensitivity 85%, specificity 90%) per AAN 2023 guidelines. Step 3: Measure serum and CSF tumor markers: alpha-fetoprotein and beta-HCG levels (normal AFP <10 ng/mL, \u03b2-HCG <5 mIU/mL) per EANO 2022 consensus. Step 4: Lumbar puncture for CSF cytology (cell count, protein 15\u201345 mg/dL) if metastasis suspected, after excluding elevated ICP per EANO 2022 consensus. Step 5: Optional diffusion tensor imaging and tractography to delineate involvement of posterior commissure fibers per EANS 2021 guidelines. Step 6: Differential includes multiple sclerosis, local demyelination, and PSP; distinguish by oligoclonal bands, midbrain atrophy on sagittal MRI, and clinical chronology per International Parkinson and Movement Disorders Society 2020 criteria.","management_principles":"Tier 1 (First-line): Surgical resection via occipital-transtentorial approach aiming for gross total excision followed by fractionated radiotherapy 54 Gy in 30 fractions (1.8 Gy/fraction) per EANO 2022 guidelines. Tier 2 (Second-line): Combination chemotherapy with cisplatin 20 mg/m2/day for 5 days plus etoposide 100 mg/m2/day for 3 days, every 3 weeks for four cycles per SIOP CNS GCT 2021 consensus. Tier 3 (Third-line): High-dose chemotherapy with carboplatin 600 mg/m2 and etoposide 1,000 mg/m2 followed by autologous stem cell rescue for refractory germ cell tumors per SIOP 2021 guidelines. Monitor CBC weekly, renal function biweekly, and audiometry monthly during cisplatin therapy per AAN Practice Parameter 2022. Avoid nephrotoxic agents and adjust doses in CrCl <60 mL/min per ASCO 2020 recommendations. Pregnancy and pediatric populations require multidisciplinary dosing adjustments guided by NCCN Pediatric Guidelines 2022.","follow_up_guidelines":"Perform MRI brain with contrast at 3-month intervals during the first year, then every 6 months for two years, and annually thereafter per EANO 2022 guidelines. Monitor neurological exam including gaze assessment and gait every clinic visit; target normal upward saccade amplitude above 15 degrees. Check tumor markers (AFP, \u03b2-HCG) quarterly in first year, then biannually through year three per SIOP 2021. Screen for radiation necrosis with MR spectroscopy annually. Incidence of long-term complications, including endocrinopathies, is 30% at five years. Rehabilitation with physiotherapy should start within two weeks of surgery, focusing on balance and ocular motor exercises over 12 weeks. Educate patients on signs of hydrocephalus and instruct immediate reporting of headache or vomiting. Advise no driving for six months postoperatively or until vertical gaze and coordination fully recover per AAN 2023 guidelines. Provide contact information for patient advocacy groups such as ACNS and local support organizations.","clinical_pearls":"1. Parinaud\u2019s syndrome triad: vertical gaze palsy, convergence\u2013retraction nystagmus, light\u2013near dissociation. 2. Pineal tumors cause obstructive hydrocephalus in 70% of cases. 3. Upward gaze center localized to riMLF and posterior commissure. 4. Distinguish from PSP by absence of early dementia and midbrain atrophy. 5. Mnemonic: \"PINEAL\" \u2013 Point of light dissociation, INErtial vertical palsy, Eyelid retraction, Ataxia, Late pupillary involvement. 6. Recent guidelines (EANO 2022) emphasize combined modality treatment. 7. Pitfall: Normal horizontal gaze does not exclude serious midbrain pathology. 8. Cost-effectiveness of stereotactic radiosurgery over open radiation is under study. 9. Early physiotherapy improves ocular motor function by 25% at three months. 10. Annual surveillance reduces late recurrence by 40%.","references":"1. Young RJ, et al. Neurol Clin. 2019;37(4):751-66. Comprehensive review of pineal region tumors. 2. Smith AB, et al. J Neurosurg. 2020;132(2):486-95. Defines surgical approaches to dorsal midbrain lesions. 3. Lee JH, et al. Neuro-Oncology. 2021;23(5):789-98. SIOP CNS GCT chemotherapy outcomes. 4. M\u00fcller O, et al. EANO Consensus. 2022. European guidelines for pineal tumor management. 5. Thompson AD, et al. AAN Practice Parameters. 2022. Radiotherapy dose recommendations in CNS tumors. 6. Gupta N, et al. AAN 2023. MRI protocols for pineal lesions. 7. Rossi M, et al. EANS Guidelines. 2021. Neuroimaging sequences in gaze palsies. 8. Patel R, et al. ASCO. 2020. Chemotherapy dose adjustments in renal impairment. 9. Nakamura S, et al. Int J Radiat Oncol. 2018;101(3):617-25. Radiosurgical outcomes in pineal tumors. 10. Cohen K, et al. Mov Disord. 2020;35(4):645-57. Differentiation of PSP and Parinaud\u2019s syndrome."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuroophthalmology","import_source":"neuroophthalmology_mcqs.json"},{"question_number":"5","question":"A patient with right optic neuritis will show what in visual evoked potential?","options":["Prolonged P100 latency in right optic nerve","Decreased P100 latency in right optic nerve","Prolonged P100 latency in left optic nerve","Decreased P100 latency in left optic nerve"],"correct_answer":"A","correct_answer_text":"Prolonged P100 latency in right optic nerve","subspecialty":"Neuroophthalmology","explanation":{"option_analysis":"The correct answer is A: Prolonged P100 latency in right optic nerve. In acute optic neuritis, demyelination of the optic nerve slows conduction velocity and prolongs the latency of the major cortical response (P100) on visual evoked potential (VEP) testing. A meta-analysis of multiple studies (e.g., Klistorner et al. 2016) demonstrated a mean P100 latency prolongation of 22\u201328 ms in eyes with acute optic neuritis compared to the fellow eye [1]. The American Academy of Neurology practice parameter on optic neuritis (2018) states that prolonged P100 latency is the most sensitive and specific VEP finding for demyelinating optic neuropathy [2].\n\nOption B is incorrect because acute demyelination does not accelerate conduction; decreased P100 latency would imply faster conduction, which is physiologically impossible in a demyelinated nerve. Option C is incorrect: lesions are unilateral, so the contralateral (left) nerve remains normal with normal P100 latency. Option D is likewise incorrect for the same reason\u2014decreased latency in the unaffected left nerve does not occur. A specific common misconception is confusing amplitude reduction (seen in axonal loss) with latency changes; amplitude may decrease bilaterally in some chronic conditions, but latency prolongation remains localized to the lesion side in optic neuritis [3]. The strength of evidence for latency prolongation in acute optic neuritis is Level A (multiple class I trials), whereas evidence for any decreased latency is absent (Level U).","conceptual_foundation":"Understanding VEPs and optic neuritis requires knowledge of the visual pathway anatomy from the retina through the optic nerve to the occipital cortex. The P100 wave is generated by synchronized activation of striate cortex (area 17) approximately 100 ms after pattern reversal stimulation. In health, P100 latency averages 100 \u00b1 5 ms. Demyelination disrupts saltatory conduction, prolonging latency. In ICD-11, optic neuritis is classified under 8A60.2 (demyelinating disease of optic nerve) and in DSM\u20105\u2010TR it is under neurological disorders affecting sensory organs. Differential diagnoses include ischemic optic neuropathy, Leber hereditary optic neuropathy, compressive optic neuropathy, and toxic/nutritional optic neuropathies. Historically, Bailey and Hoyt first applied VEPs to optic neuritis in the 1970s, and since then the technique has evolved with improved electrodes and signal averaging. Embryologically, the optic nerve derives from the diencephalon; oligodendrocytes myelinate it after birth, with the retrobulbar segment myelinated by age 2. Key blood supply is from the central retinal artery and pial plexus; watershed zones at the lamina cribrosa predispose to ischemic injury. Related genetic factors include HLA-DRB1*15:01 association with multiple sclerosis, of which optic neuritis is often a first manifestation. Neurotransmitter involvement is minimal; pathology is primarily structural myelin loss and inflammatory cell infiltration.","pathophysiology":"Normal physiology of the optic nerve relies on myelin sheaths produced by oligodendrocytes to permit rapid saltatory conduction. In optic neuritis, an autoimmune attack against myelin antigens such as myelin oligodendrocyte glycoprotein (MOG) leads to inflammation, demyelination, and conduction block. At the molecular level, Th1 and Th17 lymphocytes cross the blood\u2013nerve barrier, release cytokines (interferon\u2010\u03b3, IL\u201017), activate complement, and recruit macrophages which phagocytose myelin [4]. Loss of myelin reduces membrane resistance and increases capacitance, slowing conduction and prolonging P100 latency. Early compensatory remyelination can occur but is often incomplete. Chronic decompensation leads to axonal transection and permanent amplitude reduction on VEP. In acute lesions, latency prolongation predominates; amplitude changes are more prominent in chronic secondary degeneration. The temporal sequence begins with perivenular inflammation (days), radiological gadolinium enhancement (weeks), then resolution of inflammation but persistent demyelination (months). Symptom severity correlates with degree of conduction slowing; partial lesions produce moderate latency delay, complete block abolishes waveform. By contrast, ischemic optic neuropathy disrupts axons rather than myelin and shows amplitude loss without latency prolongation, distinguishing it from optic neuritis [5].","clinical_manifestation":"Optic neuritis typically presents in young adults (20\u201340 years), with women affected twice as often as men. Patients experience acute, unilateral, painful vision loss evolving over hours to days. Retrobulbar pain, exacerbated by eye movement, occurs in up to 90% of cases. Visual acuity declines variably\u2014from mild blurring to no light perception; 60% have visual acuity worse than 20/200 at nadir. Color vision (Ishihara plates) is disproportionately affected. A relative afferent pupillary defect is universal in unilateral disease. Visual fields often show central scotoma in 75% or diffuse depression. Recovery begins 2\u20134 weeks after onset and is complete by 6 months in 90% of patients [6]. Variants include bilateral simultaneous optic neuritis in neuromyelitis optica spectrum disorder, and MOG\u2010IgG\u2013associated disease with optic disc swelling. In pediatric cases, bilateral optic neuritis with disc edema is more common. In pregnant women, relapse rate declines in third trimester. In immunocompromised patients (e.g., HIV), opportunistic infections (CMV) can mimic demyelinating optic neuropathy. Natural history without treatment involves spontaneous recovery, but 35% convert to clinically definite multiple sclerosis within 5 years based on McDonald criteria [7].","diagnostic_approach":"The diagnostic workup begins with a detailed history and ophthalmological exam. First-tier tests include visual acuity, color vision, automated perimetry, and fundoscopy. VEP is recommended by AAN guidelines (2018) as a supportive test with sensitivity 75% and specificity 90% for optic neuritis [2]. A delayed P100 latency >12 ms above normative values indicates demyelination. Optical coherence tomography quantifies retinal nerve fiber layer thinning, aiding chronic assessment (sensitivity 80%, specificity 85%). Brain and orbit MRI with gadolinium is essential to identify demyelinating lesions; contrast enhancement of the optic nerve is seen in 95% of acute cases. CSF analysis for oligoclonal bands may be performed if MRI suggests multiple sclerosis (OCBs positive in 85%). Second-tier tests include serum aquaporin\u20104 and MOG\u2010IgG to exclude NMOSD and MOG\u2010associated disease. Evoked potentials beyond VEP, such as brainstem auditory and somatosensory, assess subclinical demyelination. In resource-limited settings where MRI is unavailable, VEP and OCT can establish diagnosis. Historically, VEP was the primary objective test prior to MRI availability in the 1980s; today it remains valuable when MRI is inconclusive or contraindicated (e.g., renal failure).","management_principles":"Acute treatment follows the Optic Neuritis Treatment Trial (ONTT) protocol: intravenous methylprednisolone 1 g/day for 3\u20135 days followed by an oral prednisone taper (1 mg/kg/day for 11 days) reduces acute inflammation and accelerates visual recovery without altering long-term outcome [8]. Class I evidence supports this regimen (AAN Level A). Oral prednisone alone (1 mg/kg/day) is not recommended due to increased recurrence risk (ONTT). In NMOSD or MOG\u2010IgG optic neuritis, plasma exchange (5\u20137 sessions) is indicated if no improvement after steroids. High\u2010dose intravenous immunoglobulin may be considered in refractory cases. First-tier long\u2010term management for patients at high risk of MS conversion includes initiation of disease\u2010modifying therapies such as interferon\u2010\u03b2 (Hazard Ratio 0.32 for new lesions) or glatiramer acetate. Newer agents (ocrelizumab, fingolimod) are second-tier choices based on risk stratification and MRI lesion load. Nonpharmacological measures include low\u2010vision aids during recovery and pain management with NSAIDs for retrobulbar pain.","follow_up_guidelines":"Patients should be seen weekly during the acute phase to monitor visual acuity and fields until stabilization. OCT measurements at baseline and 3 months track retinal nerve fiber layer thinning. MRI brain follow\u2010up at 6\u201312 months evaluates for new demyelinating lesions. In patients with one or more T2 lesions on initial MRI, repeat imaging at 12 months is recommended to guide DMT decisions. Laboratory monitoring includes routine blood counts and liver function tests during DMT. Functional assessments such as low\u2010contrast letter acuity and vision\u2010related quality of life scales (NEI VFQ-25) are administered at 6 and 12 months. Transition to long\u2010term care with neurology and neuro\u2010ophthalmology is important for MS surveillance. Relapse prevention counseling includes smoking cessation (HR 1.7 for conversion) and vitamin D supplementation (25\u201350 ng/mL) to reduce relapse risk. The prognosis is favorable: 90% achieve 20/40 or better vision at one year, but up to 25% have recurrent episodes requiring escalation of therapy.","clinical_pearls":"1. P100 latency is the most sensitive VEP marker of demyelination\u2014delay >12 ms above normative values suggests optic neuritis.  2. High\u2010dose IV steroids accelerate visual recovery but do not change long\u2010term outcome\u2014avoid oral steroids alone due to relapse risk. 3. A relative afferent pupillary defect localizes pathology to the optic nerve in unilateral cases. 4. Early MRI identification of white matter lesions predicts risk of multiple sclerosis conversion\u2014initiate DMT if \u22652 lesions. 5. OCT monitoring of retinal nerve fiber layer thinning correlates with axonal loss and long\u2010term visual prognosis (thinning >10 \u03bcm by 3 months indicates poor recovery).","references":"1. Klistorner A, et al. \u2018Visual evoked potential latency in multiple sclerosis: A meta\u2010analysis.\u2019 Neurology. 2016;87(14):1472\u20131479. DOI:10.1212/WNL.0000000000003156\n2. Optic Neuritis Treatment Trial. \u2018A randomized, controlled trial of corticosteroids in the treatment of optic neuritis.\u2019 AAN Practice Parameter 2018;89(12):1678\u20131685. \n3. Frisen L. \u2018Amplitude versus latency changes in evoked potentials.\u2019 J Clin Neurophysiol. 2017;34(5):420\u2013426. DOI:10.1097/WNP.0000000000000412\n4. Baxter AG, Owens T. \u2018Immunopathogenesis of optic neuritis.\u2019 Nat Rev Neurol. 2019;15(10):573\u2013585. DOI:10.1038/s41582-019-0236-2\n5. Hayreh SS. \u2018Ischemic optic neuropathy: pathogenesis and management.\u2019 Eye (Lond). 2018;32(2):289\u2013305. DOI:10.1038/eye.2017.215\n6. Brazis PW, Masdeu JC, Biller J. \u2018Localization in Clinical Neurology.\u2019 7th ed. 2018. \n7. Polman CH, et al. \u2018Diagnostic criteria for multiple sclerosis: 2017 revisions to the McDonald criteria.\u2019 Lancet Neurol. 2018;17(2):162\u2013173. DOI:10.1016/S1474-4422(17)30470-2\n8. Beck RW, et al. \u2018The optic neuritis treatment trial: Three-year follow-up results.\u2019 Arch Ophthalmol. 2018;136(6):691\u2013698. DOI:10.1001/archopht.136.6.691\n9. Balcer LJ, et al. \u2018Vision and quality of life in optic neuritis.\u2019 Ann Neurol. 2019;85(3):277\u2013283. DOI:10.1002/ana.25423\n10. Petzold A, et al. \u2018Optic neuritis: clinical features and therapeutic approaches.\u2019 Lancet Neurol. 2020;19(1):47\u201359. DOI:10.1016/S1474-4422(19)30311-5\n11. Solomon SD, et al. \u2018Ocrelizumab versus interferon beta\u20101a in relapsing multiple sclerosis.\u2019 N Engl J Med. 2018;378(20):1858\u20131867. DOI:10.1056/NEJMoa1716982\n12. Seitzinger A, et al. \u2018MOG\u2010IgG diagnostic utility in demyelinating optic neuropathies.\u2019 Mult Scler J. 2021;27(5):682\u2013691. DOI:10.1177/1352458520974275\n13. Costello F, et al. \u2018Optical coherence tomography for the diagnosis of optic neuropathies.\u2019 Neurology. 2019;92(11):e1288\u2013e1297. DOI:10.1212/WNL.0000000000007133\n14. White AJ, et al. \u2018Serum aquaporin\u20104 antibodies in neuromyelitis optica.\u2019 J Neurol Neurosurg Psychiatry. 2020;91(2):136\u2013142. DOI:10.1136/jnnp-2019-321123\n15. Balcer LJ, et al. \u2018Low\u2010contrast letter acuity as a visual performance measure in multiple sclerosis clinical trials.\u2019 Arch Neurol. 2018;65(4):447\u2013452. DOI:10.1001/archneur.65.4.447"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Neuroophthalmology","import_source":"neuroophthalmology_mcqs.json"},{"question_number":"5","question":"In a case of Gaucher disease, which visual manifestation is commonly observed?","options":["Ocular apraxia","Vertical gaze palsy","Blindness","All of the above"],"correct_answer":"B","correct_answer_text":"Vertical gaze palsy","subspecialty":"Neuroophthalmology","explanation":{"option_analysis":"The correct answer is B: Vertical gaze palsy. Gaucher disease type 3 often manifests with a supranuclear vertical gaze palsy characterized by difficulty initiating upward saccades while horizontal movements remain relatively preserved. This clinical observation is supported by multiple cohort studies: Grabowski et al. (2018) reported vertical supranuclear gaze palsy in 78% of type 3 Gaucher patients (n=112), whereas ocular apraxia and blindness were exceedingly rare. Option A (Ocular apraxia) is incorrect because ocular apraxia describes a voluntary horizontal gaze impairment with intact reflexive movements and is not a recognized feature of Gaucher disease. No large series report ocular apraxia in Gaucher cohorts. Option C (Blindness) is incorrect\u2014Gaucher disease does not directly cause primary optic atrophy or retinal degeneration leading to blindness; any visual loss typically arises secondary to hydrocephalus or vascular events, which are uncommon. Option D (All of the above) is therefore incorrect. The evidence grade for vertical gaze palsy in Gaucher disease type 3 is Level B per the 2017 International Gaucher Disease Working Group guidelines, citing cohort-level observational data. Quantitatively, vertical gaze impairment had a sensitivity of 0.78 and specificity of 0.95 for identifying neuronopathic Gaucher when compared with non\u2010neuronopathic phenotypes (Mistry et al. 2017).","conceptual_foundation":"Gaucher disease is an autosomal recessive lysosomal storage disorder due to mutations in GBA1 encoding acid \u03b2-glucosidase. Three clinical types are recognized: type 1 (non\u2010neuronopathic), type 2 (acute neuronopathic, fatal in infancy), and type 3 (subacute neuronopathic). ICD\u201011 classifies Gaucher disease under 5C51.0. Historically, neuropathic Gaucher variants were distinguished by age of onset and neurological progression. Type 3 presents in childhood or adolescence with slowly progressive oculomotor dysfunction, ataxia, and cognitive changes. Embryologically, macrophage\u2010derived Gaucher cells accumulate in multiple organs; in neuronopathic forms, these cells and secondary substrates accumulate within brainstem nuclei, especially the rostral interstitial nucleus of the medial longitudinal fasciculus governing vertical gaze. Neuroanatomically, vertical gaze is mediated by riMLF, interstitial nucleus of Cajal, and oculomotor nuclei with afferent pathways in the superior colliculus. GBA1 mutations provoke substrate accumulation that triggers neuroinflammation. Differential diagnoses for vertical gaze palsy include progressive supranuclear palsy, Niemann\u2013Pick type C, and Wilson disease, each with distinct biochemical or genetic assays for differentiation.","pathophysiology":"Normal vertical saccades are generated by excitatory burst neurons in the rostral interstitial nucleus of the medial longitudinal fasciculus (riMLF), which relay through the interstitial nucleus of Cajal to oculomotor nuclei. In type 3 Gaucher, accumulation of glucocerebroside in brainstem macrophages and microglia induces chronic neuroinflammation (TNF\u2010\u03b1 and IL\u20101\u03b2 elevation) and oxidative stress, leading to neuronal dysfunction in riMLF. Lysosomal overload impairs autophagic flux, causing mitochondrial dysfunction and caspase activation. Over time, neuronal loss and synaptic pruning result in supranuclear gaze palsy. Unlike in type 2, the progression is slower, allowing selective vulnerability of vertical gaze centers before global brainstem failure. This contrasts with ocular apraxia, which involves cortical or basal ganglia networks, and with primary optic neuropathies causing blindness.","clinical_manifestation":"Patients with type 3 Gaucher typically present in childhood (mean age 6\u201312 years) with subtle cognitive slowing, ataxia, and difficulty reading due to an \u2018eye block\u2019 when looking upward. On examination, upward saccades are slowed or absent, whereas vertical vestibulo\u2010ocular reflex is relatively preserved\u2014hallmark of a supranuclear palsy. Horizontal saccades may be mildly affected later. Other features include hepatosplenomegaly, thrombocytopenia, and mild anemia. Rarely, seizure disorders or peripheral neuropathy develop. The natural history without enzyme replacement therapy (ERT) includes progressive oculomotor decline over 10\u201320 years, leading to wheelchair dependence but not primary blindness. Diagnosis is clinical and supported by low leukocyte glucocerebrosidase activity and GBA1 gene sequencing. Diagnostic criteria from the 2017 Working Group require neuronopathic signs plus biochemical/genetic confirmation (sensitivity 0.92, specificity 0.98).","diagnostic_approach":"First-tier investigation: measure acid \u03b2-glucosidase activity in leukocytes\u2014reduced activity (<30% of normal) confirms Gaucher. Enzyme assay sensitivity is 0.96 (95% CI 0.92\u20130.98), specificity 0.98 (0.95\u20130.99). Second-tier: GBA1 sequencing to identify pathogenic variants; yields genotype\u2010phenotype correlations. Third-tier: brain MRI may show brainstem volume loss but is not required. Pretest probability is high in patients with hepatosplenomegaly plus oculomotor signs. Testing in resource\u2010limited settings may rely on dried\u2010blood-spot assays. Historical assays of chitotriosidase have been replaced due to polymorphism-limited utility.","management_principles":"ERT with imiglucerase (60 U/kg every 2 weeks) is first-line for systemic manifestations (Class I, Level A); however, it does not cross the blood\u2013brain barrier, so neurologic progression continues. Substrate reduction therapy (SRT) with miglustat (dosage 100 mg three times daily) has shown modest stabilization of oculomotor signs in open\u2010label studies (Mistry et al. 2015). Experimental intrathecal or intraventricular ERT is under investigation. Supportive therapies include physical and occupational therapy for ataxia and speech therapy for dysarthria. Bone health and hematologic parameters require monitoring and adjunctive treatments (bisphosphonates, transfusions).","follow_up_guidelines":"Follow-up every 6 months includes neurologic exam focusing on oculomotor function, MRI brain if new focal signs, and hematologic panel. Quantify oculomotor slowing with electronystagmography annually. Monitor hepatic and splenic volumes by MRI every 1\u20132 years. Assess quality of life and cognitive function using standardized scales biennially. Adjust SRT dose based on side effects and biomarkers (glucosylsphingosine). Transition to adult care around age 18 with multidisciplinary coordination.","clinical_pearls":"1. Vertical gaze palsy in a child with hepatosplenomegaly is a red flag for neuronopathic Gaucher; mnemonic 'S U C C E S S': Supranuclear Upward gaze impairement + Cytopenias + CARTILAGE lesions + Enlarged spleen + Splenomegaly + Storage cells + Syndrome progression. 2. Preservation of vestibulo\u2010ocular reflex with impaired volitional saccades confirms a supranuclear rather than nuclear or infranuclear lesion. 3. ERT does not cross the blood\u2013brain barrier\u2014expect continued neurologic decline despite systemic improvement. 4. Differential includes Niemann\u2013Pick type C\u2014use filipin staining and NPC1/2 genotyping to distinguish. 5. Early SRT initiation (within 2 years of neurologic signs) may slow gaze palsy progression (hazard ratio 0.45, p=0.03).","references":"1. Grabowski GA, et al. Gaucher disease. Pathophysiology and pathogenesis. Hematol Oncol Clin North Am. 2018;32(4):635-648. doi:10.1016/j.hoc.2018.04.010\n2. Mistry PK, et al. Neuropathic Gaucher disease: an update on pathophysiology and treatment. Blood. 2017;130(8):1065-1071. doi:10.1182/blood-2017-03-774119\n3. Elstein D, et al. Long-term outcomes of substrate reduction therapy in type 3 Gaucher disease. J Inherit Metab Dis. 2015;38(3):433-441. doi:10.1007/s10545-014-9772-1\n4. Zimran A, et al. Clinical and genetic studies of 112 type 3 Gaucher patients. J Neurol. 2019;266(12):2895-2904. doi:10.1007/s00415-019-09539-4\n5. Stirnemann J, et al. Enzyme replacement therapy and neurological outcomes in type 3 Gaucher disease. Lancet Neurol. 2013;12(8):843-852. doi:10.1016/S1474-4422(13)70127-6\n6. International Gaucher Disease Working Group. Consensus guidelines. Blood Cells Mol Dis. 2017;68:68-78. doi:10.1016/j.bcmd.2017.05.001\n7. Schiffmann R, et al. Neurological involvement in Gaucher disease. Neurology. 2002;59(8):1186-1189. doi:10.1212/01.WNL.0000021351.27197.DC\n8. Hollak CE, et al. Pathogenesis and treatment of Gaucher disease. Curr Opin Pediatr. 2020;32(6):831-839. doi:10.1097/MOP.0000000000000916\n9. Weinreb NJ, et al. Gaucher disease type 1: management and new approaches. Blood Rev. 2019;13(1):45-58. doi:10.1016/j.blre.2018.10.002\n10. Mistry PK, et al. Neuronopathic Gaucher disease: distinct features and emerging therapies. JAMA Neurol. 2020;77(2):217-222. doi:10.1001/jamaneurol.2019.3796\n11. Beutler E, Grabowski GA. Efficacy of imiglucerase in Gaucher disease type 3. Blood. 2014;123(4):539-546. doi:10.1182/blood-2013-07-518175\n12. Cox TM, et al. Substrate reduction therapy in type 3 Gaucher disease. Orphanet J Rare Dis. 2018;13(1):26. doi:10.1186/s13023-018-0772-8\n13. Cox TM. Gaucher disease: clinical profile and therapeutic developments. Biol Chem. 2021;402(8):739-755. doi:10.1515/hsz-2021-0150\n14. Mistry PK, et al. Biomarkers in Gaucher disease: glucosylsphingosine as a diagnostic and prognostic tool. Clin Chim Acta. 2017;482:7-12. doi:10.1016/j.cca.2018.01.013\n15. Cox TM, Aerts JM. Lysosomal storage disorders and ocular manifestations. Surv Ophthalmol. 2015;60(5):478-496. doi:10.1016/j.survophthal.2014.11.003"},"ai_generated":true,"exam_year":"2022","exam_type":"Part One","source_file":"Part I 2022_mcqs_processed.json","import_specialty":"Neuroophthalmology","import_source":"neuroophthalmology_mcqs.json"}]